Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clotrimazole + gentamicin is a topical combination drug consisting of clotrimazole, an antifungal agent, and gentamicin, an aminoglycoside antibiotic. Clotrimazole acts by inhibiting ergosterol biosynthesis in fungal cell membranes through antagonism of lanosterol 14-alpha demethylase (CYP51), leading to increased membrane permeability and inhibition of fungal growth[2][6]. Gentamicin exerts its antibacterial effect by binding to the 30S ribosomal subunit in bacteria, thereby inhibiting protein synthesis and causing bacterial cell death[5][6]. This combination is primarily used for the treatment of mixed skin infections caused by susceptible fungi (such as dermatophytes or Candida) and bacteria (such as Staphylococcus aureus or Pseudomonas aeruginosa). It is commonly formulated as a topical cream or ointment for use in both human and veterinary medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clotrimazole + gentamicin.